Hematopoietic Stem Cells Transplantation (Hsct) Market Size to grow by USD 2585.1 million between 2024-2028
According to a research report “ Hematopoietic Stem Cells Transplantation (Hsct) Market” by Application (Bone marrow transplant, Peripheral blood stem cell transplant, Cord blood transplant) Type (Autologous HSCT, Allogeneic HSCT) Geography (North America, Europe, Asia, Rest of World (ROW))- Global Forecast to 2028 published by Technavio, the market size is estimated to grow by USD 2585.1 million, at a CAGR of 6.64% during the forecast period. The global Hematopoietic Stem Cells Transplantation (HSCT) market is experiencing significant growth due to technological advancements leading to safer procedures and increased success rates. Notable innovations, such as Ranfac's Marrow Cellution technology, address concerns related to contamination and poor cellular yield in conventional transplant methods. This cutting-edge technology, which overcomes issues with traditional needles, is a game-changer in meeting the stringent cellular demands for treating various diseases, thereby fueling market expansion throughout the forecast period.
Browse market data tables, figures, and in-depth TOC on “Hematopoietic Stem Cells Transplantation (Hsct) Market” by Application (Bone marrow transplant, Peripheral blood stem cell transplant, Cord blood transplant) Type (Autologous HSCT, Allogeneic HSCT) Geography (North America, Europe, Asia, Rest of World (ROW)) Global Forecast to 2028. Download Free Sample
By Application, the Bone marrow transplant segment is projected to dominate the market size in 2024
In the realm of hematopoietic stem cells transplantation (HSCT), the autologous segment holds a significant market position. This segment entails the utilization of a patient's own hematopoietic stem cells (HSC) for transplantation. The preference for autologous HSCT is evident in the treatment of various diseases, including multiple myeloma (MM), non-Hodgkin lymphoma (NHL), Hodgkin lymphoma (HL), acute myeloid leukemia (AML), neuroblastoma, and autoimmune disorders such as systemic lupus erythematosus (SLE), systemic sclerosis, and amyloidosis. The primary advantage of autologous HSCT lies in the body's recognition of the transplanted cells, thereby reducing the likelihood of graft-versus-host disease (GvHD) and ensuring a higher success rate. Consequently, the autologous HSCT market dominance can be attributed to its extensive application in treating a broad spectrum of diseases.
By Type, Autologous HSCT segment is expected to hold the largest market size for the year 2024
The Hematopoietic Stem Cells Transplantation (HSCT) market is experiencing significant growth due to the increasing demand for bone marrow transplants. This medical procedure, also known as a stem cell transplant, replaces dysfunctional or insufficient bone marrow with healthy blood-forming stem cells. Patients diagnosed with various malignant and non-malignant disorders, including acute and chronic leukemias, adrenoleukodystrophy, aplastic anemia, and bone marrow failure syndromes, are prime candidates for bone marrow transplants. The potential for improved cure rates and enhanced survival prospects for these patients fuels the market's expansion throughout the forecast period.
North America is forecasted to hold the largest market size by region in 2024
The Hematopoietic Stem Cells Transplantation (HSCT) market represents a significant business opportunity in the healthcare sector. This market involves the use of hematopoietic stem cells for the treatment of various blood disorders and cancers. HSCT is a complex process that requires advanced technology and specialized expertise. Key players in this market include Grifols, F. Hoffmann-La Roche Ltd, and Novartis AG. Growth in this market is driven by increasing prevalence of blood disorders and advancements in cell collection and processing technologies.
The Hematopoietic Stem Cells Transplantation (Hsct) Market growth and forecasting report also includes detailed analyses of the competitive landscape of the market growth and forecasting and information about 20 market companies, including:
.
For insights on company offerings- Request a sample report!
Research Analysis Overview
The Hematopoietic Stem Cells Transplantation (HSCT) market is experiencing significant growth due to the increasing prevalence of common cancers such as lymphoma and leukemia, making it a critical area in public health. The market is driven by inorganic growth strategies, including acquisitions and collaborations, among key players. According to the World Health Organization, the prevalence of cancer is projected to increase by about 70% over the next two decades. Therapeutic cells, including stem cells, play a crucial role in immune cloaking and the development of stem cell-based medicines. Companies like Clade Therapeutics, Gamida Cell, and Magenta Biosciences are leading the way in HSCT innovation. HSCT procedures include both autologous and allogeneic transplant therapies, using therapeutic cells sourced from bone marrow, cord blood, and other sources. Healthcare expenditure on haematological disorders and transplantation procedures is expected to increase significantly due to the rising burden of diseases. However, challenges such as graft-versus-host disease (GVHD) and the high cost of treatments remain. Clinical trials are ongoing to improve outcomes and reduce side effects, making HSCT a promising area for future advancements in cancer treatment.
Market Research Overview
Hematopoietic Stem Cell Transplantation (HSCT) market is witnessing significant growth due to the increasing prevalence of common cancers such as Multiple Myeloma (MM), Non-Hodgkin Lymphoma (NHL), and Hodgkin Lymphoma (HL). According to the World Health Organization, the prevalence of cancer is projected to increase by 47% by 2025. HSCT is an essential therapeutic intervention for various haematological disorders, including lymphoproliferative disorders. The market is driven by inorganic growth strategies such as acquisitions and collaborations. For instance, Clade Therapeutics acquired Priothera to expand its portfolio of stem cell-based medicines. Similarly, Gamida Cell's NiCord cord blood product received FDA approval for the reduction of the risk of graft-versus-host disease (GVHD) in HSCT. Surgical interventions like bone marrow transplant, allogeneic transplantation, and autologous transplant therapy are common HSCT procedures. However, challenges such as immune cloaking and graft-versus-host disease (GVHD) limit the market's growth. The ongoing clinical trials are exploring new therapeutic approaches to overcome these challenges. The market's growth is influenced by healthcare expenditure on haematological disorders. Key players in the market include Magenta Biosciences, Gamida Cell, and others. The market is expected to continue its growth trajectory due to the increasing demand for stem cell transplants as a treatment for various cancers and haematological disorders. In the context of the current public health emergency, HSCT is playing a crucial role in the treatment of COVID-19 patients with haematological malignancies. The market's growth is expected to be influenced by the ongoing pandemic and the evolving regulatory landscape.
Contacts
Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
Email: media@technavio.com
Website: www.technavio.com/
